AR085163A1 - Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usos - Google Patents

Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usos

Info

Publication number
AR085163A1
AR085163A1 ARP120100455A ARP120100455A AR085163A1 AR 085163 A1 AR085163 A1 AR 085163A1 AR P120100455 A ARP120100455 A AR P120100455A AR P120100455 A ARP120100455 A AR P120100455A AR 085163 A1 AR085163 A1 AR 085163A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
amino
heteroaryl
cycloalkyl
Prior art date
Application number
ARP120100455A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46638952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085163(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of AR085163A1 publication Critical patent/AR085163A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP120100455A 2011-02-11 2012-02-10 Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usos AR085163A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161441840P 2011-02-11 2011-02-11

Publications (1)

Publication Number Publication Date
AR085163A1 true AR085163A1 (es) 2013-09-11

Family

ID=46638952

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100455A AR085163A1 (es) 2011-02-11 2012-02-10 Compuesto de 4-amino-2-butenamida, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion y usos

Country Status (24)

Country Link
US (2) US8841463B2 (enExample)
EP (1) EP2672821B9 (enExample)
JP (1) JP5931929B2 (enExample)
KR (1) KR20140048857A (enExample)
CN (1) CN103491777B (enExample)
AR (1) AR085163A1 (enExample)
AU (1) AU2012214405B2 (enExample)
BR (1) BR112013020510A2 (enExample)
CA (1) CA2827157A1 (enExample)
CL (1) CL2013002325A1 (enExample)
CO (1) CO6741219A2 (enExample)
DO (1) DOP2013000182A (enExample)
EA (1) EA023168B1 (enExample)
ES (1) ES2583091T3 (enExample)
IL (1) IL227814A0 (enExample)
MA (1) MA34961B1 (enExample)
MX (1) MX2013009279A (enExample)
PE (1) PE20140999A1 (enExample)
PH (1) PH12013501665A1 (enExample)
SG (1) SG192669A1 (enExample)
TW (1) TW201302736A (enExample)
UY (1) UY33905A (enExample)
WO (1) WO2012109415A1 (enExample)
ZA (1) ZA201306074B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
NO2699580T3 (enExample) 2014-01-24 2018-02-24
SG11201806700RA (en) * 2016-02-12 2018-09-27 Pharmaxis Ltd Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
WO2023243601A1 (ja) 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
CN1240355A (zh) * 1996-05-01 2000-01-05 伊莱利利公司 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途
US6214799B1 (en) 1996-05-14 2001-04-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
AU2002232558A1 (en) * 2000-12-12 2002-06-24 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
CN101675052A (zh) 2007-04-12 2010-03-17 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
EA201190235A1 (ru) * 2009-05-07 2012-05-30 Астразенека Аб Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
UY32827A (es) * 2009-08-12 2011-02-28 Glaxo Group Ltd Inhibidores de catepsina c
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Also Published As

Publication number Publication date
NZ614540A (en) 2015-03-27
AU2012214405B2 (en) 2015-07-23
ZA201306074B (en) 2014-04-30
DOP2013000182A (es) 2014-03-16
US8841463B2 (en) 2014-09-23
EA201391155A1 (ru) 2014-01-30
EA023168B1 (ru) 2016-04-29
AU2012214405A1 (en) 2013-04-18
JP2014506577A (ja) 2014-03-17
PE20140999A1 (es) 2014-09-11
MX2013009279A (es) 2013-10-28
CL2013002325A1 (es) 2014-01-03
JP5931929B2 (ja) 2016-06-08
CO6741219A2 (es) 2013-08-30
PH12013501665A1 (en) 2019-07-17
CN103491777A (zh) 2014-01-01
EP2672821B9 (en) 2016-11-23
US20140364476A1 (en) 2014-12-11
EP2672821A1 (en) 2013-12-18
CA2827157A1 (en) 2012-08-16
TW201302736A (zh) 2013-01-16
SG192669A1 (en) 2013-09-30
ES2583091T3 (es) 2016-09-19
EP2672821B1 (en) 2016-04-20
US9187461B2 (en) 2015-11-17
BR112013020510A2 (pt) 2016-07-12
KR20140048857A (ko) 2014-04-24
IL227814A0 (en) 2013-09-30
US20130324584A1 (en) 2013-12-05
CN103491777B (zh) 2015-05-06
MA34961B1 (fr) 2014-03-01
UY33905A (es) 2012-08-31
EP2672821A4 (en) 2014-08-06
WO2012109415A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
AR079231A1 (es) Derivados de imidazoquinolina
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
PE20141358A1 (es) Polimorfos de inhibidores de cinasas
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
PE20200008A1 (es) Isoquinolinas como inhibidores de hpk1
AR074966A1 (es) Compuestos amino-heterociclicos
AR076707A1 (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
AR086319A1 (es) Compuestos heterociclicos fusionados como moduladores de canal ionico
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos
AR071480A1 (es) Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd )
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos
MX376743B (es) Síntesis de lactonas de ácido resorcílico útiles como agentes terapéuticos
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR082004A1 (es) Compuestos de fusion de piridina
AR090376A1 (es) Compuestos herbicidas
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CO6761373A2 (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure